Molecular Dx

University of Oxford study uncovers new mutations that increase risk for hypertrophic cardiomyopathy, a common, inherited heart condition, and creates a genetic risk score able to accurately predict cases and prognosis.

DARPA identified five disease categories for which the devices should detect pathogens and biomarkers: respiratory illnesses, febrile illnesses, vector-borne illnesses, gastrointestinal illnesses, and sepsis.

Mesa Biotech has developed and commercialized a PCR-based rapid point-of-care testing platform available for detecting infectious diseases including SARS-CoV-2, Influenza A and B, respiratory syncytial virus (RSV) and Strep A.

Guardant Reveal, is a plasma-only ctDNA test for detection of early-stage colorectal cancer, with additional cancer types to follow. The minimal residue disease test, which will have a turnaround time of seven days, had been in development since 2016 under the name LUNAR-1, and was launched for research use only in 2019.

Sponsor: UltivueIn this exciting new webinar, sponsored by Ultivue, we will explore the intratumoral administration of autologous, non-manipulated myeloid dendritic cells in combination with immune checkpoint inhibitors in patients with advanced solid tumors and in combination with the oncolytic virus talimogene laherparepvec (Imlygic®) in patients with advanced melanoma in phase I clinical trials.

Normally, confirming a pneumonia diagnosis requires growing bacterial samples from patients in a lab, which is time-consuming. The new test can identify 52 different pathogens, and can be done in around four hours, without needing to grow the bacteria.

10 privately-held diagnostics developers primarily focused on liquid biopsy tests, ranked by total money raised from venture capital firms.

These ten governments have committed funding for projects that will sequence a minimum of 100,000 citizens to spur genomic medicine

Known as CopyKAT (copy number karyotyping of aneuploid tumors), the tool serves as a computational method for detecting cancerous cells amidst large and complex data sets emerging from RNA-sequencing.

Sponsor: IlluminaIn this Clinical OMICs webinar, sponsored by Illumina, we will discover how combining molecular and immune profiling's power to drive molecular-based testing is improving stratification methods and patient outcomes. Additionally, our expert panelist will showcase the impact of a scalable, comprehensive assay, and infrastructure in the context of drug development.